BMS-1

CAT: 0804-HY-19991-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-19991-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM) [1][2].
CAS Number
[1675201-83-8]
Product Name Alternative
PD-1/PD-L1 inhibitor 1
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; PD-1/PD-L1
Type
Reference compound
Related Pathways
Apoptosis; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/PD1-PDL1-inhibitor-1.html
Concentration
10mM
Purity
99.71
Solubility
DMF : 5 mg/mL (ultrasonic) |DMSO : 7.14 mg/mL (ultrasonic) |Methanol : 25 mg/mL (ultrasonic)
Smiles
O=C([C@H]1N(CC2=C(OC)C=C(OCC3=C(C)C(C4=CC=CC=C4)=CC=C3)C=C2OC)CCCC1)O
Molecular Formula
C29H33NO5
Molecular Weight
475.58
Precautions
H302, H315, H319, H335
References & Citations
[1]Zhao Y, et al. Depression Promotes Hepatocellular Carcinoma Progression through a Glucocorticoids Mediated Up-Regulation of PD-1 Expression in Tumor infiltrating NK Cells. Carcinogenesis. 2019 Feb 4.|[2]Li K, et al. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. J Drug Target. 2019 Mar;27 (3) :244-256.|[3]Zhang H, et al. Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune response. Vaccine. 2019 Apr 3;37 (15) :2090-2098.|[4]Mengyuan Li, et al. KALRN mutations promote antitumor immunity and immunotherapy response in cancer. J Immunother Cancer. 2020 Oct;8 (2) :e000293.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products